Clinical Trials Logo

Myasthenia Gravis clinical trials

View clinical trials related to Myasthenia Gravis.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05218096 Terminated - Myasthenia Gravis Clinical Trials

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Start date: April 27, 2022
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams [mg], 180 mg) in participants with generalized myasthenia gravis (gMG). Safety will be monitored throughout the study.

NCT ID: NCT05132569 Terminated - Myasthenia Gravis Clinical Trials

Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis

URSA
Start date: December 3, 2021
Phase: Phase 3
Study type: Interventional

This was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tolebrutinib compared with placebo in adult participants aged 18 to 85 years old with moderate-to-severe generalized myasthenia gravis (gMG), who received Standard of Care (SoC). The double-blind (DB) treatment period of 26 weeks comprised of 7 site visits followed by a 2-year open label extension (OLE) period with quarterly visits. The efficacy of tolebrutinib versus placebo during the DB period was assessed by clinical evaluations, including scales based on physician examination or direct participant feedback i.e., patient reported outcomes (PROs). These evaluations continued during the OLE to measure long term efficacy and safety.

NCT ID: NCT03896295 Terminated - Clinical trials for Generalized Myasthenia Gravis

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

Start date: August 6, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG)

NCT ID: NCT03579966 Terminated - Clinical trials for Myasthenia Gravis, MuSK

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Start date: June 11, 2018
Phase: Phase 3
Study type: Interventional

Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.

NCT ID: NCT03059888 Terminated - Myasthenia Gravis Clinical Trials

Trial of Orencia in Patients With Myasthenia Gravis

Start date: April 12, 2017
Phase: Early Phase 1
Study type: Interventional

This pilot research study is being done to see if the drug abatacept (Orencia ®) will be helpful in treating patients with myasthenia gravis (MG) who do not respond satisfactorily to other drugs that are used to suppress the immune system. Abatacept has been successful in treating experimental MG in laboratory animals, and this study is to determine its effectiveness in patients with MG.

NCT ID: NCT02102594 Terminated - Clinical trials for Rheumatoid Arthritis

Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

TAVAB
Start date: October 2014
Phase: Phase 2
Study type: Interventional

The aim of this pilot study is to investigate the application of proteasome inhibitor Bortezomib (Velcade®, approved for therapy of multiple myeloma) in patients with therapy-refractory antibody-mediated autoimmune diseases. The investigators hypothesis is that the proteasome inhibition will lead to reduced antibody titers and improved clinical outcome.

NCT ID: NCT01828294 Terminated - Myasthenia Gravis Clinical Trials

Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis

SIMM
Start date: October 2011
Phase: Phase 1
Study type: Interventional

The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients may or may not be receiving anticholinesterase agents. A common treatment for patients with this disease includes the administration of intravenous immunoglobulin (IVIG), which is a plasma protein that is given to help maintain adequate antibody levels to prevent infections and decrease the symptoms of the disease of Myasthenia Gravis. This study is being done to test if giving this medication in a subcutaneous form (into the fat of the abdomen, legs and thighs) will be better tolerated for patients with Myasthenia Gravis.

NCT ID: NCT01268280 Terminated - Myasthenia Gravis Clinical Trials

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

Start date: December 2010
Phase: Phase 2
Study type: Interventional

The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).

NCT ID: NCT00995722 Terminated - Clinical trials for Ocular Myasthenia Gravis

Efficacy of Prednisone In the Treatment of Ocular Myasthenia

EPITOME'
Start date: December 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and tolerability of prednisone in patients diagnosed with ocular myasthenia. Funding Source - FDA OOPD

NCT ID: NCT00727194 Terminated - Myasthenia Gravis Clinical Trials

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.